Abstract: Abstract：Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Induction chemotherapy is still a first-line treatment for AML. However, due to the high toxicity of AML-induction chemotherapy and the characteristics of high failure rate and high recurrence rate, chemotherapy is limited in patients with AML. In recent years, the treatment of desitabine and azacytidine has been deeply studied in the epigenetic therapy of AML, which has shaken the status of induction chemotherapy in patients with AML. With the development of AML biology, more and more targets have been found to affect the biological process of AML. The targeting drugs for AML can be classified into three categories. The first type is mutant site inhibitors, such as FLT3 and IDH inhibitors. The second type is inhibitors that regulate metabolism or signaling pathway, such as Bcl-2 antagonists and epigenetic drugs. And the third category is targeted cytotoxic drugs. The most promising drugs for AML-targeted treatment were inhibitors regulating metabolism or signaling pathway reported in the 2017 American Society of Hematology Annual meeting. Clinical trial report of Venetoclax, a Bcl-2 inhibitor, won the best abstract of this meeting. This article reviews the progress of Bcl-2 inhibitors in the treatment of AML.

Key words: leukemia, myeloid, genes, Bcl-2, Bcl-2 , Venetoclax, Navitoclax